Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Covidh Technologies Ltd (BSE: 534920) met on March 10, 2026 and approved a change of the company's name to 'iSERA Lifesciences Limited,' with name reservation already secured from the Ministry of Corporate Affairs. The name change signals a clear pivot from its current identity toward the pharmaceutical and life sciences sector. The registered office is being shifted within Pune from Shukrawar Peth to Sadhu Vaswani Chowk, Camp. Four new directors have been recommended for a 5-year term, subject to shareholder approval at an EGM on April 2, 2026: Mr. Dhairyasheel Yadav (18+ years in pharma/biotech) and Mr. Nandkumar Kadam (20+ years in biopharma R&D) as Executive Directors, plus Mr. Pratap Deshmukh and Ms. Ritu Garad as Non-Executive Non-Independent Directors. The new leadership team's profiles are heavily weighted toward microbiology, biopharmaceuticals, and life sciences, reinforcing the strategic direction implied by the rebranding.
Shareholders should view this as a significant strategic rebrand into the life sciences space, supported by a management overhaul with sector specialists. The name change and new director appointments are subject to EGM approval on April 2, 2026, and could shift the stock's identity and investor interest toward pharma/biotech themes, though actual business transition details remain to be seen.